[NT 10-Q] AIM ImmunoTech Inc. SEC Filing

Rhea-AI Filing Summary

Aim ImmunoTech Inc. filed a notice that it will be late filing its Form 10-Q for the quarter ended September 30, 2025, citing delays in completing its review and the need for more time to compile and verify data. The company expects to file the report within the allowed extension period.

Preliminary figures for the three months ended September 30, 2025 show revenues of approximately $26,000, down from about $35,000 a year earlier, while net loss is expected to narrow to roughly $3,284,000 from about $3,700,000. For the nine-month period, revenue is expected to decrease to around $67,000 from about $125,000, with net loss improving to roughly $9,783,000 from about $11,353,000.

Net loss per share – basic and diluted – is expected to be about $(1.57) for the quarter versus $(6.00) a year earlier, and $(8.18) for the nine months versus $(21.00) in the prior-year period, indicating a smaller loss spread over the company’s share base.

Insights

Financial Reporting and Earnings Quality Specialist

Late 10-Q with small revenue base, lower revenues, but moderately improved net loss and loss per share.

Aim ImmunoTech filed an NT 10-Q indicating it cannot file its Q3 2025 Form 10-Q on time due to delays in completing the required review. The company plans to use the allowed short extension under Rule 12b-25, which typically limits the delay to a few calendar days, and states it expects to file within that extension period. This indicates a timing issue in financial statement preparation rather than a disclosed change in reporting framework or auditor.

Preliminary results show a very small revenue base and declining revenues. For the quarter ended September 30, 2025, revenues are expected to be about $26,000, down from roughly $35,000 a year earlier. For the nine-month period, revenues are expected at around $67,000 vs. about $125,000 in the prior-year period, signaling weaker top-line activity over both short and year-to-date horizons.

Loss metrics show some improvement. The company expects a quarterly net loss of about $3.284 million vs. about $3.7 million in the prior-year quarter, and a nine-month net loss of roughly $9.783 million vs. about $11.353 million. Net loss per share – basic and diluted – is expected at approximately $(1.57) for the quarter, compared with $(6.00) a year ago, and $(8.18) for the nine months vs. $(21.00) previously. The combination of a filing delay, declining revenues, and still sizable losses, offset by lower loss levels and reduced loss per share, points to a mixed but not dramatically changed financial picture. The key near-term item to watch is the actual Form 10-Q when filed within the extension window after September 30, 2025 for full detail on cash use and operating drivers.

		OMB APPROVAL
	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549	OMB Number: 3235-0058 Expires: September 30, 2028 Estimated average burden hours per response 2.50
	FORM 12b-25	SEC FILE NUMBER
		CUSIP NUMBER
	NOTIFICATION OF LATE FILING

(Check one):

☐

Form 10-K

☐

Form 20-F

☐

Form 11-K

☒

Form 10-Q

☐

Form 10-D

☐

Form N-CEN

☐

Form N-CSR

For Period Ended: September 30, 2025

☐

Transition Report on Form 10-K

☐

Transition Report on Form 20-F

☐

Transition Report on Form 11-K

☐

Transition Report on Form 10-Q

For the Transition Period Ended:_____________________________

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I — REGISTRANT INFORMATION

Aim ImmunoTech Inc.

Full Name of Registrant

Former Name if Applicable

2117 SW Highway 484

Address of Principal Executive Office (Street and Number)

Ocala, FL 34473

City, State and Zip Code

SEC 1344 (01-19) Potential persons who are to respond to the collection of information contained in this Form are not required to respond unless the Form displays a currently valid OMB control number.

Board of Governors of the Federal Reserve System 0MB Number 7100-0091 Approval expires February 28, 2026

PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

	(a)	The reason described in reasonable detail in Part III of this Form could not be eliminated without unreasonable effort or expense;
☒	(b)	The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
	(c)	The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III – NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

The Registrant is unable to file its Quarterly Report on Form 10-Q for the period ended September 30, 2025, within the prescribed time due to delays in completing the required review. Additional time is needed for management to compile and verify the data to be included in the report. The Registrant expects to file within the permitted extension period.

(Attach extra Sheets if Needed)

Robert Dickey IV		610		864-6470
(Name)		(Area Code)		(Telephone Number)

PART IV — OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

Yes ☒ No ☐

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Yes ☒ No ☐

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. See attached.

2 of 4

Aim ImmunoTech Inc.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date	November 17, 2025	By	/s/ Robert Dickey IV
			Robert Dickey IV
			Chief Financial Officer

INSTRUCTION: The Form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the Form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the Form.

ATTENTION

Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

GENERAL INSTRUCTIONS

	1.	This Form is required by Rule 12b-25 (17 CFR 240.12b-25) of the General Rules and Regulations under the Securities Exchange Act of 1934.
	2.	One signed original and four conformed copies of this Form and amendments thereto must be completed and filed with the Securities and Exchange Commission, Washington, D.C. 20549, in accordance with Rule 0-3 of the General Rules and Regulations under the Act. The information contained in or filed with the Form will be made a matter of public record in the Commission files.
	3.	A manually signed copy of the Form and amendments thereto shall be filed with each national securities exchange on which any class of securities of the registrant is registered.
	4.	Amendments to the notifications must also be filed on Form 12b-25 but need not restate information that has been correctly furnished. The Form shall be clearly identified as an amended notification.
	5.	Electronic filers. This form shall not be used by electronic filers unable to timely file a report solely due to electronic difficulties. Filers unable to submit a report within the time period prescribed due to difficulties in electronic filing should comply with either Rule 201 or Rule 202 of Regulation S-T (§232.201 or §232.202 of this chapter) or apply for an adjustment in filing date pursuant to Rule 13(b) of Regulation S-T (§232.13(b) of this Chapter).
	6.	Interactive data submissions. This Form shall not be used by electronic filers with respect to the submission or posting of an Interactive Data File (§232.11 of this chapter). Electronic filers unable to submit or post an Interactive Data File within the time period prescribed should comply with either Rule 201 or 202 of Regulation S-T (§232.201 and §232.202 of this chapter).

3 of 4

ATTACHMENT TO PART IV-ITEM (3) OF FORM 12B-25

AIM ImmunoTech, Inc.

WITH RESPECT TO ITS FORM 10-Q FOR THE PERIOD ENDED SEPTEMBER 30, 2025

The Registrant estimates that its results of operations for the period ended September 30, 2025, as reflected in its consolidated statements of operations to be included in its Form 10-Q for the period ended September 30, 2025, will reflect the following changes:

For the three month period ended September 30, 2025, the Registrant expects to report a decrease in revenues to approximately $26,000 from approximately $35,000 for the three month period ended September 30, 2024. For the nine month period ended September 30, 2025, the Registrant expects to report a decrease in revenues to approximately $67,000 from approximately $125,000 for the nine month period ended September 30, 2024. Also, for the three month period ended September 30, 2025, the Registrant expects to report a net loss of approximately $3,284,000 compared to a net loss of approximately $3,700,000 for the three month period ended September 30, 2024. For the nine month period ended September 30, 2025, the Registrant expects to report a net loss of approximately $9,783,000 as compared to a net loss of approximately $11,353,000 for the nine month period ended September 30, 2024.

Finally, for the three month period ended September 30, 2025, the Registrant expects to report net loss per share - basic and diluted - of approximately $(1.57) compared to net loss per share – basic and diluted - of $(6.00) for the three month period ended September 30, 2024. For the nine month period ended September 30, 2025, the Registrant expects to report net loss per share - basic and diluted - of approximately $(8.18) compared to net loss per share – basic and diluted - of $(21.00) for the nine month period ended September 30, 2024.

4 of 4

FAQ

Why did Aim ImmunoTech (AIM) file an NT 10-Q for September 30, 2025?

Aim ImmunoTech filed an NT 10-Q because it could not complete its Quarterly Report for the period ended September 30, 2025 on time due to delays in completing the required review and the need for more time for management to compile and verify the data.

When does Aim ImmunoTech expect to file its delayed Q3 2025 Form 10-Q?

The company states that it expects to file its Quarterly Report on Form 10-Q for the period ended September 30, 2025 within the permitted extension period provided by Rule 12b-25.

What preliminary Q3 2025 revenue does Aim ImmunoTech (AIM) expect to report?

For the three months ended September 30, 2025, Aim ImmunoTech expects to report revenues of approximately $26,000, compared to approximately $35,000 for the same period in 2024.

How is Aim ImmunoTech’s expected Q3 2025 net loss changing versus last year?

For the three months ended September 30, 2025, the company expects a net loss of approximately $3,284,000, compared with a net loss of about $3,700,000 for the three months ended September 30, 2024.

What nine-month 2025 results does Aim ImmunoTech anticipate disclosing?

For the nine months ended September 30, 2025, Aim ImmunoTech expects revenues of approximately $67,000 versus about $125,000 a year earlier, and a net loss of roughly $9,783,000 compared to about $11,353,000 for the nine months ended September 30, 2024.

How is Aim ImmunoTech’s net loss per share expected to change for Q3 and nine months 2025?

For Q3 2025, net loss per share – basic and diluted – is expected to be approximately $(1.57), compared to $(6.00) in Q3 2024. For the nine months ended September 30, 2025, it is expected to be about $(8.18), versus $(21.00) for the same period in 2024.